A Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment (ANDHI)
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2018
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ANDHI
- Sponsors AstraZeneca
- 28 Aug 2018 Planned End Date changed from 10 May 2019 to 13 Aug 2020.
- 28 Aug 2018 Planned primary completion date changed from 10 May 2019 to 13 Aug 2020.
- 05 Apr 2018 Planned number of patients changed from 800 to 630.